In the intensive care unit, alcohol intake above the NIAAA recommendations regardless of the existence of an Alcohol Use Disorder (AUD), was associated with an increased risk of death and longer time on ventilator. This rises the hypothesis that unhealthy alcohol use may lead to specific issues when weaning the mechanical ventilation (i.e. agitation or its related complications) regardless of AUD or withdrawal syndrome. Thus, we proposed to use baclofen off-label to avoid agitation. The data presented in this article is related to the research article entitled: "Pharmacokinetics and toxicity of high-dose baclofen in ICU patients" Vourc'h et al., 2019 Data provided in this submission includes 1) the detailed methods for baclofen assay by mass spectrometric detection, 2) the supplementary population pharmacokinetic analysis presenting observed concentration vs. population or individual predicted concentration (raw data of the latter is also available), and 3) the algorithm for the adaptation of baclofen daily doses according of DOI of original article: https://doi
Data
In a surgical intensive care, unhealthy alcohol users received off-label baclofen to prevent agitation during the awakening phase, trying to ease mechanical ventilation weaning. We created an algorithm for baclofen dose adaptation according to estimated glomerular filtration rate. The starting day of baclofen is referred as "day 1": Patients received a loading dose of baclofen via an enteral feeding tube on day 1. Then daily doses were divided into 3 intakes until the weaning of mechanical ventilation. The pharmacokinetic study started on day 3: Samples were taken just before administration of baclofen and then from 30 min to 8 hours after administration (total of 8 samples). This article comprises: the method used to treat and analyze the samples (see Methods for baclofen assay), data files generated with the NONMEM software version 7.3 (Icon Development Solutions, Hanover, USA) based on baclofen assays (see a chromatogram example in Fig. 1 Value of the data Baclofen may be an option to prevent agitation in the ICU for unhealthy alcohol users, but no randomized study is available up to now. The high variability of pharmacokinetic properties in the critically ill, notably when kidney injury occurs, urged us to assess the risk of toxicity in this population. The proposed algorithm to adjust doses to renal clearance did not lead to overshoot the toxic plasma concentration of 1.1 mg/L [2] regardless of renal failure. These results were used to design a multicenter randomized study to assess the relevance of baclofen vs. placebo to prevent agitation in unhealthy alcohol user with or without AUD in the ICU [3] .
pharmacokinetic analysis in Fig. 2 . Finally, it includes the algorithm for baclofen doses adjustment according to the renal function (see Table 2 ).
Experimental design, materials, and methods

Methods for baclofen assay
Plasma samples were mixed with acetonitrile containing the internal standard (baclofen-d4) and centrifuged. The supernatant was transferred into glass tubes and then evaporated at 37 C under a stream of nitrogen. Samples were recovered with mobile phase and then injected into the chromatographic system Agilent 1200 series (Agilent, Les Ulis, France). Separations were performed on an Aquasil . The method was found to be accurate (inaccuracy <10%) and showed good precision (imprecision <10%) The limit of quantitation is 0.01 mg/L. A chromatograph corresponding to a patient plasma sample is presented in Fig. 1 .
Additional analysis for the pharmacokinetic model
The population pharmacokinetic analysis was performed using NONMEM software version 7.3 (Icon Development Solutions, Hanover, USA). The diagnostic plots corresponding to the final and base pharmacokinetic models are presented in Fig. 2 . The raw data used to produce the graphs of the final model are presented in Table 1 .
These plots show an improved correlation between observed concentrations (DV) and predicted concentrations ( 
Treatment adjustment in patients with renal failure
The following protocol of sedation was applied to adjust baclofen dose to renal function (see Table2) . Fig. 1 . Chromatograms of a patient (A) plasma sample (0,17 mg/L) and the internal standard (B). These chromatograms with a high intensity signal for a low baclofen plasma concentration show the specificity and the high sensitivity of the assay. This assay is specific because no interfering chromatographic peak was found with a retention time close to the retention time of the baclofen peak (3.07 min). This assay is sensitive because the peak intensity (about 5.0 Â 10 4 cps) is highly superior to the background noise of the baseline although the baclofen plasma concentration (0,17 mg/l) is low. 
